🟠 Moderate Evidence
A prospective cohort study published in PLOS Medicine has identified molecular signatures in lung fluid that precede chronic lung allograft dysfunction (CLAD)—the leading cause of late-term lung transplant failure—by months, potentially enabling earlier intervention before irreversible damage occurs. Researchers at the University of Melbourne analysed 56 lung transplant recipients over 30 months, finding that excessive sphingolipids and immune recruitment signals in broncho-alveolar lavage fluid preceded CLAD onset, suggesting endothelial damage is detectable long before clinical decline.
Key takeaways
- Elevated sphingolipids and vascular dysfunction genes appear months before CLAD diagnosis in transplant recipients
- Early-stage lung transplants show distinct microbial and immune patterns; CLAD-precursor signatures differ significantly
- Multi-omics profiling (microbial, metabolic, lipid, and gene data combined) outperforms single-marker approaches in predicting disease
- Current diagnosis of CLAD occurs only after irreversible lung damage; these biomarkers could enable pre-symptomatic detection and earlier treatment
Study at a Glance
| Source | PLOS Medicine |
| Study type | Prospective cohort (hypothesis-generating) |
| Sample size | N = 56 CLAD-free patients; 13 CLAD-free vs. 13 CLAD-positive comparisons |
| Population | Lung transplant recipients aged ≥18 years |
| Country | Australia (single-centre) |
| Duration | Up to 30 months post-transplant |
Molecular timeline: from transplant to CLAD onset
Key biomarker changes in broncho-alveolar lavage fluid (0–30 months post-transplant)
Source: Iacono et al., PLOS Medicine, 2024 | Georgian Medical Journal News
Why current CLAD diagnosis comes too late
Current clinical practice diagnoses CLAD only after lung transplant recipients experience a persistent decline in forced expiratory volume (FEV1) — typically a 20% drop from their best post-transplant baseline. By this point, researchers explain, the underlying endothelial damage and fibrotic remodelling have progressed substantially, leaving limited window for therapeutic intervention. This reactive approach is the primary reason why long-term lung transplant survival lags behind other solid organs, with median survival around 5–6 years, according to transplant registries.
Dr. Benjamin J. Marsland, lead investigator at the University of Melbourne’s Department of Immunology, and colleagues sought earlier molecular signatures that might precede clinical decline. Rather than measuring a single biomarker, they adopted a “multi-omics” strategy—simultaneously profiling bacterial composition, metabolite levels, lipid species, and gene expression patterns in serial broncho-alveolar lavage (BAL) fluid samples collected from transplant recipients.
In patients destined to develop CLAD, elevated sphingolipids and upregulation of genes controlling vascular dysfunction (HAPLN3, HS3ST3B1, SULF2) and immune cell recruitment (CXCR1, CSF3R, CEACAM1) appeared months before any decline in lung function, suggesting endothelial dysregulation is the initiating event.
— Prof. Benjamin J. Marsland, University of Melbourne, PLOS Medicine, 2024
A distinct microbial and immune landscape in stable versus failing transplants
The study revealed sharp divergence in broncho-alveolar lavage composition between recipients who remained stable and those who developed CLAD. In the first 6 months post-transplant—a period of natural immune adjustment—stable recipients exhibited diminished overall bacterial diversity, paradoxically coupled with increased abundance of Staphylococcus and Candida species and robust upregulation of innate immune genes (FDR < 0.05). Notably, elevated nitric oxide (NO) metabolism marked this early phase, suggesting active endothelial protective mechanisms.
By months 6–12 in stable recipients, the microbial landscape rebalanced, T-cell genes including CD3, GZMA (granzyme A), IL2RB, CD28, CD40LG, and LCK reactivated, and tissue repair pathways became dominant—indicating restoration of immune homeostasis after tapering of intensive immunosuppression. This pattern matches the expected physiological recovery observed in successful lung transplantation.
In contrast, patients who subsequently developed CLAD exhibited a strikingly different signature: elevated sphingolipids (a lipid class implicated in vascular inflammation and endothelial permeability), combined with robust upregulation of genes controlling glycocalyx remodelling and vascular infiltration (HAPLN3, HS3ST3B1, SULF2, CHST2, CSGALNACT1) and immune cell recruitment markers (CXCR1, CSF3R, SELL, CXCL2, CEACAM1). This dysregulated endothelial and immune signature preceded clinical CLAD diagnosis by a median interval investigators did not explicitly state but contextually spanned months 12–24 post-transplant.
Implications for transplant surveillance and intervention timing
If validated in independent cohorts, these biomarkers could transform post-transplant monitoring from reactive (waiting for FEV1 decline) to predictive (intervening before irreversible damage). The ability to identify at-risk recipients 6–12 months before CLAD manifestation would create a critical window for intensified immunosuppression, targeted anti-inflammatory therapy, or experimental interventions aimed at preventing endothelial dysfunction.
Translating these findings into clinical practice will require prospective validation in multicenter cohorts, standardisation of BAL collection and multi-omics analysis protocols, and definition of diagnostic thresholds. The authors note this was a hypothesis-generating study at a single transplant centre (University of Melbourne), limiting generalisability. Collaboration with transplant programmes across different healthcare systems—including varied immunosuppressive regimens, donor characteristics, and recipient demographics—will be essential before these biomarkers can inform routine clinical algorithms.
What this means
Frequently asked questions
What is chronic lung allograft dysfunction (CLAD) and why is it so difficult to detect early?
CLAD is a pathological process of airway fibrosis and vascular remodelling that leads to progressive and irreversible loss of lung function in transplant recipients. Current diagnosis relies on spirometry (lung function testing), which only becomes abnormal after substantial structural damage has already occurred. There are no non-invasive clinical tests to detect the early molecular events—such as endothelial dysregulation—that precede this decline, making early intervention impossible under current practice.
How were these biomarkers discovered, and are they already in clinical use?
Researchers performed multi-omics profiling—simultaneous analysis of microbial, metabolic, lipid, and gene expression data—from broncho-alveolar lavage fluid (lung fluid collected via routine post-transplant bronchoscopy). The findings are from a single-centre hypothesis-generating study and are not yet in clinical use. Validation in larger, multicenter cohorts, development of standardised testing protocols, and regulatory approval will be necessary before these biomarkers can guide routine transplant care.
Could these biomarkers apply to other organ transplants?
This study focused exclusively on lung transplantation. However, the concept of multi-omics surveillance for early detection of allograft dysfunction may be relevant to heart, kidney, and liver transplantation, where late rejection and fibrosis similarly limit long-term survival. Separate studies would be required to test whether analogous endothelial and immune signatures predict dysfunction in other solid organs.
These findings represent an important step toward precision monitoring in lung transplantation. Future research should focus on prospective validation across diverse transplant populations, refinement of biomarker algorithms, and integration with immunological data (e.g., donor-specific antibodies) to create a comprehensive, multi-modal risk prediction model. The ultimate goal is to shift CLAD management from late-stage rescue to early intervention, potentially extending transplant survival and improving quality of life for recipients globally.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
